News

• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe
• Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP

Research

• The cost of developing drugs and use of generics
• Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
• Repurposing generic drugs can save time and money
• Availability of medicines and the sustainable development of the national health system in Russia

General

• UK NHS faces drug shortages
• High drug bills? Turn to your pharmacist for help
• FDA Office of Generic Drugs publishes 2021 annual report
• COVID-19 vaccine produced in Latin America

News

• Lucentis biosimilars approved in the UK and Korea
• New adalimumab biosimilars prepare to launch in Canada, US and Europe
• FDA approves Amneal’s bevacizumab biosimilar
• Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized

Research

• Patient perspectives on biosimilars in a high uptake country
• Biosimilar adoption and prescribing in Japan: a physician opinion survey
• Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
• Totality of evidence supporting approval of Avsola in the treatment of IBD

General

• HHS new study on biosimilar use and expanded trials will include older patients
• Needle-free delivery of biological drugs from Rani and Progenity
• British Columbia adds coverage for three new enoxaparin biosimilars
• Biocomparables approved in Mexico

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links